Jump to content

Dengue vaccine for children to be available in Thailand in two years


webfact

Recommended Posts

Dengue vaccine for children to be available in two years

BANGKOK, 25 July 2014 (NNT) – A dengue fever vaccine for children will become available in no more than two years, according to the National Vaccine Institute.


Dr. Sophon Mekthon, the director-general of the Department of Disease Control, said on Thursday at the 6th National Vaccine Conference in Bangkok that Thailand has gained global acceptance for its ability to provide basic vaccinations for more than 90% of its targeted population. Thailand has also been seen as being among ASEAN member countries that possess 'vaccine integrity'.

Dr. Charung Mueangchana, director of the National Vaccine Institute, said at the same event Thailand, Vietnam, Malaysia, Philippines and Indonesia are slated to collaboratively develop vaccines against the four strains of dengue fever.

The trial conducted involved 10,000 people who lived in areas that carried high risk of dengue fever. The vaccines were 56.5% successful in protecting against dengue, whereas the severity of dengue fever was reduced in as much as 88.5% of cases.

Dr. Charung added that Thailand will possess children's vaccines for dengue fever within two years. The vaccines will be valid for children aged between two and 14 years, and each vaccination course will provide protection for two years.

[nnt]2014-07-25[/nnt]

Link to comment
Share on other sites

Sanofi first announced the end of a phase 3 trial in Asia in April. http://sanofipasteur.com/en/articles/theworld-s-first-large-scale-dengue-vaccine-efficacy-study-successfully-achieved-its-primary-clinical-endpoint.aspx

 

Then announced The Lancet results analysis in July: http://www.sanofipasteur.com/en/articles/first-ever-dengue-vaccine-candidate-to-show-efficacy-against-dengue-fever-and-dengue-haemorrhagic-fever-in-asia.aspx

 

A huge followup study on the results is underway till 2017. Plus there is still the Latin America phase 3 trial either underway or about to begin. 

 

The OP story says two years for a vaccine. Nowhere in what I read from Sanofi is there a promise of a commercial vaccine in two years. Just more trials. 

 

As always, vaccine trials and analyses are always vast multinational efforts. So, what a strange story, to be kind. 

 

 

Edited by Kaoboi Bebobp
  • Like 1
Link to comment
Share on other sites

 

Not so fast....this is NOT a Thai thing only.... it's Produced by French pharmaceutical giant Sanofi Pasteur,

 

"it had limited efficacy against dengue 2, one of four dengue virus serotypes in circulation. First infections are typically mild; but for poorly understood reasons, infection with a second serotype can lead to severe disease."

 
Edited by wilcopops
Link to comment
Share on other sites

 

A few notes from the press.... the OP seems to suggest this is a done deal when it most certainly isn't.

 

BBC - "Sanofi-Pasteur, the company funding the research, plans to apply for approval once the results of its second trial across Latin America and the Caribbean have been analysed."

 

 

 

Fierce Biotech....

 

Dengue comes in four serotypes, and while Sanofi's treatment did well against variants 1, 3 and 4, it charted just 34.7% efficacy in serotype 2, missing statistical significance in one of Asia's most common forms of the disease. Furthermore, the researchers note, the vaccine's efficacy increased with patient age, with the youngest patients deriving the least benefit.

 

 

considering half the world's population is at risk of contracting dengue, "this vaccine candidate, despite moderate overall efficacy, could have a substantial effect on public health,"

 

Sanofi is waiting on the results of another 20,000-patient Phase III study, expected later this year, before filing for regulatory nods around the globe. If approved, Sanofi's treatment would be the only vaccine on the market for a tropical disease that infects up to 100 million people a year, according to the World Health Organization.

 

The company has spent more than $1.5 billion developing its dengue candidate, and now, with positive late-stage results in hand, Sanofi has glimpsed the finish line, hoping to launch the vaccine next year.

 

 

http://www.fiercebiotech.com/story/sanofis-15b-dengue-vaccine-shows-phase-iii-promise-questions-linger/2014-07-11

Link to comment
Share on other sites

Thai bullshit. There is NO vaccination against dengue fever. If multinationals like the the Swiss Novartis, Roche and other multinationals are unable to develop a vaccine against dengue, why should Thailand be able to do this? If there would be a chance, all the multinationals would have already a medicament against dengue fever. But dengue is not malaria, it is more difficult.

Link to comment
Share on other sites

Thai bullshit. There is NO vaccination against dengue fever. If multinationals like the the Swiss Novartis, Roche and other multinationals are unable to develop a vaccine against dengue, why should Thailand be able to do this? If there would be a chance, all the multinationals would have already a medicament against dengue fever. But dengue is not malaria, it is more difficult.


Sanofi IS a multinational! They are conducting trials in Thailand and and other countries around the world.....e.g West Indies.......Thailand is just jumping the gun on the conclusions.
Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Recently Browsing   0 members

    • No registered users viewing this page.







×
×
  • Create New...